US 10758488

I'll search for authoritative information on this specific patent number, including any recent litigation activity.

Let me find the actual claim text and check the CAFC dockets for recent activity.

Let me retrieve the actual claim language for this patent (12 claims total).

US Patent 10,758,488 B2 — Analyst Summary

Source of record: Full patent text (Google Patents, fetched 2026-10-01) plus live searches of patent databases and litigation dockets. Note on scope: my web tools returned bibliographic data, the specification/abstract, and litigation excerpts, but I was not able to pull the verbatim issued claim text of the '488 patent itself. The claim overview below is reconstructed from the specification and from claim language quoted in litigation documents, and should be verified against the printed patent. I flag confidence levels throughout.

1. Bibliographic data

Prosecution chain (as printed on the face of the patent): This is a continuation of Ser. No. 13/071,369 (filed Mar. 24, 2011, now abandoned), which claims benefit of U.S. Provisional 61/317,212 (filed Mar. 24, 2010). The '488 in turn spawned later continuations (e.g., US 10,873,110; US 10,813,885; US 10,959,956; US 10,966,931; US 11,090,269; US 11,207,270). A Certificate of Correction was issued (correcting claim 3, col. 28).

2. Abstract (verbatim)

"Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form."

3. Plain-language overview of the independent claims

Caveat: medium confidence. The patent has 12 claims. Based on the specification and on identical limitations appearing in the '488 patent family (e.g., US 11,207,270, a Jazz continuation), the claims appear to break down into two independent claims — one composition/dosage-form claim and one method-of-treatment claim. The verbatim wording could not be retrieved with my tools.

Independent claim 1 (dosage form — high confidence that a composition claim is first):
A controlled-release dosage form containing gamma-hydroxybutyrate (GHB) or a pharmaceutically acceptable salt (e.g., sodium oxybate). The form is time-dependent (its release is driven by an aqueous-environment-triggered coating, not by GI pH), and it is defined by its in-vitro dissolution profile — measured in USP Apparatus 2, deionized water, 37 °C, 50 rpm paddles. As quoted in Jazz's litigation pleadings, the profile recites limitations such as:

• at least/greater than about 30% of the GHB released by 1 hour; and
• greater than about 90% of the GHB released by 8 hours.

Structurally (per the specification and the sibling '270 claims), the dosage form is described as a controlled-release (CR) core (drug-loaded, ~90–98 wt% drug) bearing a functional overcoat that regulates release; the coating may be a water-insoluble base polymer such as ethylcellulose with a pore former (20–50 wt%), and the whole may be topped with a moisture-barrier (important because sodium oxybate is highly hygroscopic) and an immediate-release (IR) coat in an integrated unit dose.

Independent claim 11 (method of treatment — medium confidence):
A method of treating cataplexy or excessive daytime sleepiness associated with narcolepsy in a patient in need thereof by delivering a GHB formulation that comprises an immediate-release portion and a solid sustained-release portion. The sustained-release portion comprises a functional coating over a drug-containing core, where the coating includes one or more methacrylic acid–methyl methacrylate copolymers at about 20%–50% by weight of the coating; and the form is defined by dissolution limits (e.g., sustained-release portion releases > about 40% by 4–6 h; formulation releases ≥ about 30% at 1 h and > about 90% at 8 h).

The remaining 10 claims appear to be dependent claims narrowing drug amount (e.g., 750 mg or 1,000 mg, or 500 mg–12 g dosing), salt selection (Na, Ca, K, Li, Mg), excipients (hydrogenated vegetable oil/castor oil), dissolution limits, and the IR:CR drug ratio (e.g., IR = 10–50% of total drug; IR:CR ≈ 1:2 to 1:4). Again — flag as unverified.

4. Litigation status (as of April 2026)

The '488 patent has been litigated in the Jazz Pharmaceuticals vs. Avadel CNS Pharmaceuticals dispute over once-nightly sodium oxybate (Lumryz) in the U.S. District Court for the District of Delaware (consolidated actions under, e.g., No. 1:21-cv-00691-GBW / 1:21-cv-01594-GBW).

• Asserted by Jazz in its May 12, 2021 complaint (asserting several oxybate patents, including the '488).
• February 2024 jury trial (Feb. 26–Mar. 1, 2024). Per Avadel's public SEC filing, the jury returned a verdict of no infringement as to U.S. Patent No. 10,758,488 (other patents in the trial were resolved differently, including a finding of infringement of U.S. 11,147,782). Confidence: medium — this is a direct quote from an Avadel filing, but the sentence was truncated in the search result; the exact verdict package across all asserted patents should be confirmed in the judgment.
• Federal Circuit No. 24-2274, decided May 6, 2025 (Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC, Lourie, Reyna, Taranto, JJ.). This appeal primarily addressed the '782 patent permanent injunction (new clinical trials / open-label extension / IH-indication approval); the court reversed-in-part, vacated-in-part, and remanded. The '488 is listed among the patents associated with this docket on the patent's Google Patents page, though the opinion's analysis centered on the '782 patent.
• CAFC No. 23-1186 is also listed on the '488 patent page as a related Federal Circuit matter.
• Settlement: On October 21, 2025, Avadel and Jazz entered a settlement/license agreement; on October 24, 2025, the parties filed a joint stipulation of dismissal with prejudice, entered by the court October 27, 2025.

2026 docket check: My searches surfaced no separate 2026 CAFC activity specifically on the '488 patent. The 24-2274 appeal was decided in May 2025 and the underlying Delaware cases were dismissed with prejudice in late October 2025, so the '488-specific litigation appears concluded (subject to the post-remand injunction proceedings on the '782 patent).

5. Uncertainty notes (explicit)

• Verbatim claim text not retrieved. The specification, abstract, and claim-family language are well corroborated, but I could not open the issued claims of US 10,758,488 directly within my tool budget. Treat the claim overview as a well-grounded reconstruction, not a quotation.
• Which patents were in the February 2024 trial and the precise per-patent verdicts should be confirmed against the Delaware judgment; the Avadel filing states "no infringement for U.S. Patent No. 10758488," which I have reproduced literally rather than corrected.
• Assignee spelling: Google Patents lists "Clark Allphin"; some third-party databases render it "Alphin"/"Allphin." Inventor names are interpreted literally as printed on the patent.

Primary sources consulted: Google Patents full text (https://patents.google.com/patent/US10758488/en); USPTO PDF (patentimages.storage.googleapis.com/.../US10758488.pdf); FreePatentsOnline (freepatentsonline.com/10758488.html); Federal Circuit opinion, No. 24-2274 (cases.justia.com, May 6, 2025); Unified Patents litigation records (portal.unifiedpatents.com); Avadel/Jazz SEC disclosures.

I'll research litigation involving US patent 10758488 using patent litigation sources.

Let me search for more specific details on the cases and their outcomes.

Let me get details on the Federal Circuit appeals and any PTAB proceedings involving this patent.

I've reached my research step limit. Here is what I could confirm about litigation involving US Patent 10,758,488 ("Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances," assigned to Jazz Pharmaceuticals, Inc.). All of the litigation I found is between Jazz and Avadel concerning the narcolepsy/oxybate drug LUMRYZ.

Cases involving US 10,758,488

1. Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC — D. Del. (the lead patent case)

• Plaintiff: Jazz Pharmaceuticals, Inc. (later joined by Jazz Pharmaceuticals Ireland Ltd.; consolidated with C.A. Nos. 21-1138 and 21-1594)
• Defendant: Avadel CNS Pharmaceuticals, LLC (and Avadel Pharmaceuticals plc)
• Jurisdiction: U.S. District Court for the District of Delaware (Judge Gregory B. Williams)
• Case number: C.A. No. 21-691-GBW (consolidated with 21-1138-GBW and 21-1594-GBW)
• Filing date: May 12, 2021
• The '488 patent's role: Jazz's First Complaint asserted the '488 patent together with U.S. Pat. Nos. 8,731,963; 10,813,885; 10,959,956; and 10,966,931. Avadel counterclaimed for declaratory judgment of non-infringement and invalidity of the '488 patent (Counts IV and V of its counterclaims; it also sought correction of inventorship/derivation-based invalidity). Jazz ultimately narrowed its asserted claims at trial to claims 7 and 11 of the '488 patent and claim 24 of the '782 patent.
• Outcome / status: Trial held Feb. 26 – Mar. 1, 2024. On March 4, 2024, the jury returned a verdict of no infringement of the '488 patent, and found that Avadel had failed to prove the '488 patent invalid (no lack of written description/enablement; no improper inventorship or derivation). The jury did find infringement of U.S. Pat. No. 11,147,782 (the '782 patent) with damages of $234. The '488 patent survived the validity challenge but was held not infringed by LUMRYZ.
  • Verdict form: https://storage.courtlistener.com/recap/gov.uscourts.ded.75471/gov.uscourts.ded.75471.527.0.pdf
  • Claim construction opinion: https://www.ded.uscourts.gov/sites/ded/files/opinions/21-691_0.pdf
  • Docket summary: https://www.drugpatentwatch.com/p/litigation/casename/index.php?query=Jazz+Pharmaceuticals%2C+Inc.+v.+Avadel+CNS+Pharmaceuticals%2C+LLC%7C1%3A21-cv-00691
• Note: The later permanent injunction (Aug. 27, 2024) and the related Federal Circuit appeal flow from the '782 patent finding, not from the '488 patent, because the '488 patent was found not infringed.

2. Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. — D. Del. (Avadel's offensive case touching the '488 patent)

• Plaintiff: Avadel CNS Pharmaceuticals, LLC and Avadel Pharmaceuticals plc
• Defendant: Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Ltd.
• Jurisdiction: U.S. District Court for the District of Delaware (Judge Gregory B. Williams)
• Case number: C.A. No. 1:22-cv-00487-GBW
• Filing date: April 14, 2022
• The '488 patent's role: This was not an infringement suit over the '488 patent. Avadel alleged breach of confidentiality agreements, trade-secret misappropriation, and correction of inventorship under 35 U.S.C. § 256, alleging Jazz copied subject matter into its patents — expressly including the '488 patent — from Avadel's confidential disclosures and publications. Avadel also brought antitrust counterclaims. Jazz's motion to dismiss and motions to stay were denied (opinion dated May 24, 2024).
  • Docket summary: https://www.drugpatentwatch.com/p/alphasignals/litigation/casename/index.php?query=Avadel+CNS+Pharmaceuticals%2C+LLC+v.+Jazz+Pharmaceuticals%2C+Inc.%7C1%3A22-cv-00487
• Outcome / status: Resolved by the October 2025 global settlement (see below).

3. Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC — C.A. No. 22-941-GBW (D. Del.)

• Related Delaware action (filed 2022) concerning U.S. Pat. No. 8,731,963 (the "REMS patent") plus Avadel antitrust counterclaims. The '488 patent is discussed in the court's background because the '488 and '782 patents were tried in the related C.A. No. 21-691 case, but the '488 patent is not itself the patent-in-suit in 22-941.
  • Opinion: https://cases.justia.com/federal/district-courts/delaware/dedce/1:2022cv00941/79495/94/0.pdf

Federal Circuit appeals (same litigation family)

The Google Patents family record lists two CAFC filings for this patent family — No. 23-1186 and No. 24-2274 (portal.unifiedpatents.com). Based on the record:

• 23-1186 — Jazz's appeal of the order requiring delisting of the REMS/'963 patent from the Orange Book; the Federal Circuit affirmed on Feb. 24, 2023 (this does not concern the '488 patent).
• 24-2274 — an appeal arising from the February 2024 patent trial/injunction phase (after the March 4, 2024 verdict). The Federal Circuit issued an opinion on May 6, 2025 reversing/vacating portions of the district court's injunction (relating to open-label extensions, new clinical trials, and seeking FDA approval for additional indications).

Caveat: I could not independently verify, within my research steps, the precise scope of 24-2274 or confirm whether any ruling on the '488 patent itself was appealed. I did not find any confirmed PTAB (IPR/PGR) proceeding involving the '488 patent.

Final outcome — global settlement (October 2025)

All of these cases were resolved by a global Settlement and License Agreement dated October 21, 2025 between Avadel CNS and Jazz:

• Jazz paid Avadel $90 million and waived royalties/damages on LUMRYZ sales through Sept. 30, 2025.
• Avadel pays Jazz royalties (3.85% on narcolepsy net sales; 10% on certain future indications) through Feb. 18, 2036.
• Jazz granted Avadel a perpetual worldwide license to any past/present/future patents (including the '488 patent family) assertable against LUMRYZ.
• The Delaware Lawsuits — including Jazz v. Avadel, C.A. No. 21-691, and Avadel v. Jazz, C.A. No. 22-487 — were dismissed with prejudice (joint stipulation filed Oct. 24, 2025; entered Oct. 27, 2025).

Sources:

• https://investors.avadel.com/static-files/bdc9a49c-44db-4043-b097-dce798f49b8b
• https://www.quinnemanuel.com/the-firm/news-events/landmark-settlement-victory-for-jazz-pharmaceuticals/
• https://www.law360.com/mlex/articles/[2403010](/patent/2403010)/jazz-to-pay-90-million-to-settle-avadel-s-us-antitrust-claims-over-over-xyrem

Summary table

Bottom line: The only known litigation over US 10,758,488 is the Jazz–Avadel dispute (both the Jazz patent-infringement action, C.A. No. 21-691-GBW, and Avadel's inventorship/trade-secret action, C.A. No. 22-cv-00487-GBW), all in the District of Delaware. The '488 patent was held not infringed but not proven invalid at the March 2024 trial, and all related cases were settled and dismissed with prejudice in late October 2025. I did not find any other defendant, any ITC action, or any confirmed PTAB proceeding involving this specific patent. Details of Federal Circuit No. 24-2274 and any '488-specific appellate issues should be verified directly against the CAFC docket, as I could not fully confirm them here.

I'll verify the canonical "no PTAB activity" signal against live sources before finalizing.

Proceedings overview

Total AIA trial proceedings on US 10,758,488: 0. There is no inter partes review, post-grant review, or covered business method review on file for this patent — the USPTO Open Data Portal returns an empty trial-proceeding list, and my independent searches (PTAB E2E / PTAB Decisions indices, CourtListener, law-firm and litigation-tracker dockets, and news coverage of the Jazz–Avadel dispute) surfaced no petition, no institution decision, no FWD, and no PTAB appeal naming this patent. Because there is nothing to break down by status, the usual buckets (active / claims invalidated / claims sustained / settled / institution denied) are all zero.

Bottom-line defensive posture. This is not a "hardened" patent in the PTAB sense — it is an untested one. The '488 patent has never been through an AIA trial, so (a) no claim has been canceled and no claim has been confirmed, and (b) no § 315(e) estoppel attaches to anyone, which leaves the full IPR ground set on the table for a new petitioner. That is the good news for a defendant. The bad news is that validity was litigated in district court and Jazz won that fight: on 2024-03-04 the Delaware jury found Avadel had not proven the '488 patent invalid (no lack of written description/enablement, no improper inventorship/derivation) — it lost on non-infringement instead. So the realistic defensive play on the '488 is not "the patent is already dead," it is "here is an untested IPR docket plus a proven non-infringement theory."

Proceedings by patent

None — no AIA trial proceeding exists for US 10,758,488

The structured "PTAB proceedings on file" block returned no rows, and live searching confirms the vacancy. I have no proceeding number, petitioner, panel, or FWD to report for this patent, and I will not manufacture one.

What I checked and what I found:

Timing note (why there is no PGR, and why IPR is still open): The '488 patent issued 2020-09-01 with a 2010-03-24 priority date. The PGR window under 35 U.S.C. § 321(c) closed nine months after issuance (≈2021-06-01) and is now permanently unavailable. IPR, by contrast, has no post-issuance deadline — the only timing constraint is the § 315(b) one-year bar running from service of a complaint alleging infringement of the patent.

Nearest analogue in the same portfolio (context only — this is NOT the '488 patent and NOT a proceeding on this patent): Jazz's earlier sodium-oxybate REMS patent, U.S. Pat. No. 8,731,963, was subject to IPR and its claims were held unpatentable as obvious, a result the Federal Circuit affirmed in Jazz Pharms., Inc. v. Amneal Pharms., LLC, 895 F.3d 1347 (Fed. Cir. 2018). That demonstrates Jazz's oxybate patents are PTAB-vulnerable in general, but the '963 patent belongs to a different family (drug-distribution/REMS) than the '488 patent (controlled-release formulation). I flag it as a pattern signal, nothing more.

⚠️ Contradiction flagged (do not rely on it). A PatSnap "Lumryz Narcolepsy IP Landscape" blog page contains the sentence: "Jazz has filed inter partes review (IPR) petitions and district court litigation against Avadel, asserting multiple patent claims." I could not corroborate that Jazz filed any IPR petition against Avadel, and it is inconsistent with the well-documented record (Jazz was the patent owner/plaintiff in the Delaware cases; Avadel was the accused infringer). I treat that statement as likely AI-generated error. It is not a proceeding, it has no number, and it should not be cited as evidence of PTAB activity on the '488 patent.

Strategic summary

Claim status of US 10,758,488: nothing CANCELED, nothing CONFIRMED, everything UNTESTED at the PTAB. The patent has 12 claims. Claim 1 is the sole independent claim (a formulation having immediate-release and sustained-release portions, the sustained-release portion comprising a core with a functional coating of methacrylic acid–methyl methacrylate copolymer(s) at about 20–50 wt% of the coating, with a specified dissolution window, and an immediate-release portion carrying about 10–50 wt% of the GHB); claims 2–12 are dependent. In the Delaware case Jazz asserted claims 1–12, then narrowed to claims 7 and 11 at trial against LUMRYZ. All 12 claims remain live and enforceable on the face of the patent.

Estoppel landscape — a rare clean slate. Because no IPR was ever filed, § 315(e)(2) estoppel bars nobody. A new petitioner is not restricted by anything Avadel (or anyone else) raised or could have raised. Practically, this means the full IPR ground set is available: §§ 102/103 over the art of record, art not before the examiner, and § 112 written-description/enablement grounds as the PTAB applies them under SAS (all challenged claims, all grounds). Compare this to the usual scenario where a district-court defendant first litigated invalidity and its privies are estopped — that does not apply here.

Pattern signals. (1) No serial petitioner and no defensive aggregator: Unified Patents, RPX, and similar entities have not touched this patent (the "Unified Patents" hits in the family record are litigation docket links, not IPR filings). (2) The patent owner did not need the PTAB because it was on offense: Jazz filed and litigated multiple Delaware suits, and Avadel contested validity in court (jury, 2024-03-04) rather than at the Board. (3) The parties walked away from all of it: a global Settlement and License Agreement dated 2025-10-21 granted Avadel a perpetual, worldwide license to any past/present/future Jazz patent assertable against LUMRYZ — including the '488 family — and the Delaware actions were dismissed with prejudice (entered 2025-10-27). So today there is neither an active litigant nor an active petitioner on this patent.

The bad news for a defendant. Avadel ran a full invalidity case in district court and lost — the jury found the '488 patent not invalid (no written-description/enablement failure, no improper inventorship or derivation), and the '488 survived while the '782 patent was found infringed. That verdict is not binding in an IPR, but it tells you the Board will be looking at a patent that a jury already declined to invalidate. Conversely, Avadel won on non-infringement of the '488, which is where the real defensive leverage historically sat here.

Expiry. Anticipated expiration is 2031-03-24 (pre-PTA; per the Google Patents family record). Any IPR filed now would be decided well before expiry, so there is still commercial runway to justify the filing if you are being asserted against.

Recommended next steps

1. Say it plainly to your client: there is no PTAB precedent to lean on for this patent. No FWD exists to quote; no claim has been canceled; no institution decision exists. If a demand letter from Jazz (or a successor/assignee) cites the '488 patent, you cannot say "claims 1–5 are dead." You can say the patent has never been challenged at the PTAB, that no estoppel constrains you, and that a jury has already found LUMRYZ does not infringe it.
2. Build the IPR from the Avadel invalidity record — it is public and free. Avadel's invalidity contentions identified a specific, court-ready art set for the "Jazz Sustained Release Patents," including the '488 patent: Alaux 2003 (U.S. 6,514,531), Conte 1997 (U.S. 5,594,030), Couch 2005 (U.S. 6,913,768), Handbook of Pharmaceutical Excipients (5th ed. 2006), Hu 2006, Jones 2004 (Rapra Review Reports), Lecomte 2003 (J. Control. Release 89:457), Liang 2006 (U.S. Pub. 2006/0210630) — which is the very reference the '488 specification disparages, making it the natural lead exhibit — Majeed 1986, Miller 2008 (Aqueous Polymeric Film Coating), Monteith 2009 (EP 2 034 970), Savaşer 2005, and Tabandeh 2003. See Jazz's First Amended Answer to Avadel's Counterclaims in C.A. No. 21-691 (D. Del.), which reproduces the list: https://litigationtracker.law.georgetown.edu/wp-content/uploads/2025/01/Jazz-Pharmaceuticals-Inc._2022.02.25_JAZZ-PHARMACEUTICALS-INC.S-FIRST-AMENDED-ANSWER-TO-AVADEL-CNS-PHARAMCEUTICALS-LLCS-COUNTERCLAIMS.pdf
3. Calibrate the § 112 theory before you file. Avadel's derivation/written-description attack was aimed principally at the MAMM-copolymer limitations and the USP-apparatus-2 dissolution conditions as later-added claim features, and Avadel's expert (Dr. Klibanov) argued the original claims lacked support for those terms. The jury rejected the theory for the '488, so treat that as a district-court finding you must overcome with Board-specific framing — cleanly presented prior art under §§ 102/103, not a re-run of the district-court derivation narrative.
4. Watch the § 315(b) clock. If you have been served with a complaint asserting the '488 patent, you must petition within one year of service. If you have not been served, you have no statutory deadline — and no bar — which gives you the option of a pre-emptive IPR.
5. Verify the canonical list before relying on this memo. The absence of PTAB activity here is drawn from the ODP structured list plus my web searches on 2026-10-01. Confirm directly at PTAB E2E (https://ptab.uspto.gov/) and the USPTO PTAB Decisions index (https://www.uspto.gov/patents/ptab/decisions) that no recently indexed proceeding has appeared, since the ODP ingest can lag recent filings.
6. Do not overlook the litigation pipeline that outlives the PTAB question. The 2025-10-21 settlement immunized LUMRYZ, but Jazz's oxybate portfolio is frequently re-asserted (Jazz's disclosures note new Avadel infringement suits against Xywav filed Dec. 2024–Apr. 2025). A patent that was never IPR'd once can be IPR'd later — by you.

Sources: https://patents.google.com/patent/US10758488/en | https://ptab.uspto.gov/ | https://www.uspto.gov/patents/ptab/decisions | https://storage.courtlistener.com/recap/gov.uscourts.ded.75471/gov.uscourts.ded.75471.527.0.pdf (jury verdict form, D. Del. C.A. 21-691) | https://cases.justia.com/federal/appellate-courts/cafc/24-2274/24-2274-2025-05-06.pdf (Fed. Cir. 24-2274, Jazz v. Avadel, 2025-05-06) | Jazz Pharms., Inc. v. Amneal Pharms., LLC, 895 F.3d 1347 (Fed. Cir. 2018) ('963 REMS patent family — context only)

I'll research the assignment record for US 10,758,488 using the USPTO assignment sources and related databases.

Let me look for the specific reel/frame records and the assignment history.

Let me dig for specific reel/frame numbers, the security agreement record, and inventor backgrounds.

I've gathered what's confirmable. Note: I hit my research step limit before retrieving the exact reel/frame numbers, so I'm flagging which fields I verified versus which need direct Assignment Center confirmation.

Assignment Record — US Patent 10,758,488 B2

Sources: Google Patents legal-events record for US10758488B2 (fetched 2026-10-01); USPTO news/assignment references surfaced in Jazz–Avadel litigation filings; SEC/court exhibits. Primary verification source for reel/frame: https://assignmentcenter.uspto.gov/ and https://assignment.uspto.gov/patent/index.html (search patent 10,758,488).

Verification caveat (important): The Assignment Center lists two post-issuance legal-events records for this patent, and I confirmed the parties, conveyance types, and recording dates from the Google Patents legal-events table. I was not able to retrieve the specific reel/frame numbers within my available research steps — those should be read off the Assignment Center record directly. I have not fabricated reel/frame values.

Inventors

• Allphin is well documented as a Jazz Pharmaceuticals formulation scientist. He appears as first-named inventor across the Jazz oxybate family (e.g., US 11,147,782; US 10,398,662 "GHB formulation"; US 8,591,922 / 8,901,173 "Gamma-hydroxybutyrate compositions"), and he was deposed in Jazz v. Avadel as Jazz's corporate designee (deposition transcript dated Oct. 21, 2022, D. Del. C.A. No. 21-691, D.I. 581). He testified live at the February 2024 trial.
• Unusual-pattern check — not present. This is a single-inventor-pair, employed-inventor filing, not a case of all inventors departing the original assignee. Allphin remained at Jazz at least through the 2024 trial; there is no evidence of inventor departure preceding a portfolio sale (there was no sale).
• Minor date discrepancy to flag: The authoritative patent text states priority date 2010-03-24 and filing date 2018-07-02, and that this case is a continuation of Ser. No. 13/071,369 (filed Mar. 24, 2011). Google Patents' sidebar shows the priority date as 2010-03-23 and Unified Patents shows it as 2010-03-23 / application date 2018-07-01 — a one-day artifact. The previously generated litigation section correctly used the patent-text dates (2010-03-24 / 2018-07-02); I treat those as controlling.

Original assignee

• Entity on the face of the patent: Jazz Pharmaceuticals, Inc., a Delaware corporation (principal place of business historically 3180 Porter Drive, Palo Alto, CA; the Jazz U.S. operating subsidiary).
• Primary line of business: Specialty biopharmaceutical company. Jazz ships products embodying oxybate technology: XYREM® (sodium oxybate oral solution, FDA-approved 2002) and XYWAV® (calcium/magnesium/potassium/sodium oxybate, approved July 2020). The '488 patent is one of the "Sustained Release Patents" that Jazz asserted over its oxybate franchise (see litigation section, above).
• Continuity: The application was filed by Jazz as a continuation (2018-07-02); Jazz was already assignee of the 2011 parent application, so the inventor→Jazz assignment merely memorialized the pre-existing obligation to assign.
• Current status: Operating and solvent. Jazz Pharmaceuticals plc (Irish parent, NASDAQ: JAZZ) remains an active commercial-stage company; the U.S. subsidiary is a co-borrower under the May 5, 2021 credit facility (see below). No bankruptcy, acquisition of the assignee, or dissolution. (Historical note: Jazz was near insolvency around 2009–2010 — before this patent's 2010 priority filing — and recapitalized/recovered, so the classic "distressed-seller" precondition for a fire-sale is absent here.)

Assignment timeline

Two recorded post-issuance legal events exist. Both are shown below.

1. 2018-08-27 (recorded) — Reel/Frame [not retrieved; confirm at Assignment Center]

• Conveyance: Assignment
• Assignor: ALLPHIN, CLARK PATRICK; PFEIFFER, JAMES FREDERICK (joint inventors)
• Assignee: Jazz Pharmaceuticals, Inc.
• Correspondent: Not confirmed from available sources. Note: the prosecution correspondent of record for this family is Cooley LLP / Jazz Pharmaceuticals, 1299 Pennsylvania Ave., NW, Suite 700, Washington, DC 20004 (per USPTO PTOL-85 notices of record in the related cases). That is the prosecution attorney of record, which is not necessarily the attorney who recorded the assignment. I could not verify the assignment-record correspondent, so I am not asserting it.
• Context: Routine inventor-to-employer assignment (in-house obligation to assign), recorded ~8 weeks after the 2018-07-02 continuation filing. Not an acquisition and not a transfer to an asserter.

2. 2021-05-05 (recorded) — Reel/Frame [not retrieved; confirm at Assignment Center]

• Conveyance: Security Agreement (collateral pledge / grant of security interest — not a transfer of title)
• Assignor: Cavion, Inc.; Celator Pharmaceuticals, Inc.; Jazz Pharmaceuticals Ireland Limited; Jazz Pharmaceuticals, Inc. (multi-grantor collateral package)
• Assignee: U.S. Bank National Association (as collateral trustee)
• Correspondent: Not confirmed. (A syndicated-finance collateral filing; the recording agent is typically bank/finance counsel rather than patent-prosecution counsel. I could not verify a name.)
• Context: Securitization / secured financing. This is the U.S.-law collateral perfection step for the Credit Agreement dated May 5, 2021 (Bank of America, N.A. as administrative agent; U.S. Bank as collateral trustee) entered to finance Jazz's acquisition of GW Pharmaceuticals plc. The 7/488 patent was one of a large pool of Jazz-group patents and applications pledged as collateral. It does not change beneficial ownership; Jazz Pharmaceuticals, Inc. remains the record owner.

Terminal ownership / encumbrance status: The chain terminates at Jazz Pharmaceuticals, Inc. (operating company). No assignment out of Jazz to any third party (no LLC, no NPE) is recorded. In Oct. 2025 Jazz granted Avadel a perpetual worldwide license to the '488 family as part of the global settlement; that is a license, not a recorded title transfer, so title remains with Jazz.

Timeline diagram

timeline
    title Ownership of US 10758488
    2010 : Priority application filed by Jazz
    2011 : Parent application filed
    2018 : Continuation application filed
         : Inventor assignment to Jazz recorded
    2020 : Patent issued to Jazz Pharmaceuticals
    2021 : Security agreement recorded to US Bank
         : Jazz sues Avadel on oxybate patents
    2024 : Jury finds no infringement of 488
    2025 : Settlement grants Avadel a license

NPE / troll-pattern signals

Verdict

Operating-company assertion.

Justification: The patent was filed and remains owned by Jazz Pharmaceuticals, Inc., the commercial manufacturer of XYREM®/XYWAV® sodium oxybate — a product embodying the claimed GHB controlled-release technology. The only recorded post-issuance events are (a) the routine inventor→Jazz assignment recorded 2018-08-27 and (b) a security interest to U.S. Bank N.A. recorded 2021-05-05 (collateral for the May 2021 GW acquisition financing), which does not transfer title. Jazz, not any NPE, sued direct competitor Avadel in D. Del. C.A. No. 21-691 (filed 2021-05-12), where the jury found the '488 not infringed but not proven invalid (Mar. 4, 2024); the dispute ended in the October 2025 global settlement granting Avadel a license. No shell-entity, known-asserter, cascading-transfer, pre-litigation-transfer, bankruptcy, privateering, or defensive-aggregation signal is present.

Verify at: https://assignmentcenter.uspto.gov/ (search patent number 10,758,488) — retrieve the two reel/frame entries and their recorded correspondents to complete the "Assignment timeline" fields flagged above.

I'll research US Patent 10,758,488 and its cited prior art. Let me start with searches on the patent and its references.

Let me get the complete list of cited references from the patent's front page.

Let me get the complete cited references list and the patent's claims.

Prior-Art Analysis — US Patent 10,758,488 B2

Note on scope/limitations: My live-search budget for this task was exhausted before I could pull the complete "References Cited" front page (all 100+ US references, the foreign-document list, and the examiner's NPL citations). The tables below reflect the references I did retrieve and verify. I flag explicitly where the record is incomplete so it is not treated as exhaustive. I did not auto-correct any patent number; all identifiers are reproduced literally.

1. Patent identification (literal)

Discrepancy flagged: The Google Patents family record lists priority as 2010‑03‑24, whereas the Unified Patents portal lists priority 2010‑03‑23, application date 2018‑07‑01, and expiration 2031‑03‑23. These are one-day offsets and appear to be database/DST artifacts; per the strict rule I am reporting both literally rather than reconciling them. The previously generated litigation section used 2010‑03‑24, which is consistent with the authoritative full text.

Governing law for §102: The application claims benefit to a 2010 provisional / 2011 non-provisional, i.e., before the AIA first‑inventor‑to‑file provisions apply (March 16, 2013). Pre‑AIA 35 U.S.C. §102 therefore controls. Critical practical consequence: references published after 2010‑03‑24 are not §102(a)/(b) prior art unless they qualify under §102(e) (a US patent granted, or US application published, on an application filed before the applicant's invention date). Much of the cited art on the face of the '488 patent post‑dates the priority date and is best characterized as applicant IDS material / background, not anticipatory art.

2. Claim framing

From the granted-claim text I retrieved, claim 1 is the lead formulation claim:

A formulation comprising immediate release and sustained release portions, each comprising GHB or a pharmaceutically acceptable salt thereof, wherein (a) the sustained release portion comprises a functional coating deposited over a core and releases > about 40% of its GHB by about 4–6 h (USP Apparatus 2, DI water, 37 °C, 50 rpm); (b) the immediate release portion comprises about 75%–98% GHB by weight, and the GHB in the IR portion is about 10%–50% by weight of the GHB in the formulation; (c) the formulation releases at least about 30% of its GHB by 1 h; and (d) releases > about 90% of its GHB by 8 h.

• Claim 5 — sustained-release portion comprises hydrogenated vegetable oil, hydrogenated castor oil, or mixtures.
• Claim 6 — calcium, lithium, potassium, sodium or magnesium salt of GHB, or mixtures.
• Claim 7 — the sodium salt of GHB (sodium oxybate). (Claim 7 was one of the two claims Jazz asserted at trial.)
• Claim 11 — I was unable to retrieve the exact text of claim 11 within my search budget. It was the second asserted claim. I therefore cannot confidently map references to claim 11's specific limitations and flag this as a gap.

3. References cited on the face of the patent — US patent documents

The following were retrieved from the FreePatentsOnline "US Patent References" list for 10,758,488. Prior-art-eligible under pre-AIA §102 is assessed against the ~2010 priority date.

(Truncation note: the FPO list continued past the point I retrieved, ending around US 8,731,963 → "201…". Additional US references beyond that point were not captured.)

4. References cited on the face of the patent — foreign documents

From the Unified Patents "Patent Art (162)" listing and the family record:

5. Non‑patent / specification‑cited literature

• H. D. Moldofsky et al., J. Musculoskeletal Pain, 1, 49 (1993) and Psychosom. Med., 37, 341 (1975) — fibromyalgia sleep EEG; therapeutic background only.
• Scharf et al., J. Rheumatol., 25, 1986‑1990 (1998) — open‑label GHB in fibromyalgia.
• Mamelak et al., Biol. Psych., 12, 273‑288 (1977); Broughton et al. (1976, 1979, 1980) — GHB/narcolepsy therapy.
• L. Borgen et al., J. Clin. Pharmacol., 40, 1053 (2000) — PK of oral sodium oxybate (t½ ≈ 45 min).
• US 2006/0210630 (Liang) — re‑cited in the specification as describing pH‑dependent IR + delayed‑release GHB.
• Int. J. Colorectal Dis. 2001;16(4):211‑5 and Curr. Gastroenterol. Rep. 2006;8(4):266‑72 — IBS/fibromyalgia gastric‑emptying variability rationale.

None of the NPL is a formulation disclosure capable of anticipating the structural/coating claims; they support enablement/background and the PK rationale.

6. §102 anticipation analysis (top candidates)

For a reference to anticipate under §102, it must disclose each and every limitation of the claim, arranged as claimed; the §102(b) references must also be published more than one year before the U.S. filing date (critical date ≈ 2009/2010).

(a) US 2006/0210630 A1 — Liang et al. (published 2006‑09‑21) — §102(b)

• Disclosure: oral GHB formulations comprising an immediate‑release component and a delayed‑release component; the delayed‑release component is pH‑dependent.
• Potentially anticipates: the broad concept of claims 1, 6, 7 (a formulation with IR + SR GHB portions; GHB salts, including sodium). It is the single most relevant anticipatory reference because it teaches the same two‑component architecture.
• Why it may not be anticipatory: Claim 1 requires specific in‑vitro dissolution performance (>40% by 4–6 h; ≥30% by 1 h; >90% by 8 h) plus a specified IR loading (75–98% w/w) and IR:total GHB ratio (10–50%), and a functional‑coating‑over‑core structure. Liang's pH‑dependent mechanism is expressly distinguished in the '488 specification. Anticipation would require the examiner/defendant to show these parameters are inherently met; otherwise the comparison is an obviousness (§103) argument, not §102.
• Bottom line: strongest §102 candidate for the generic IR+CR GHB concept; weaker for the performance‑limited claims as granted.

(b) WO 2007/103200 A2 — Watson (published 2007‑09‑13) — §102(b)

• Disclosure: oral controlled‑release formulations for sedative/hypnotic agents.
• Potentially anticipates: the controlled‑release platform limitations (functional coat/rate‑controlling polymer over a core) if the reference's sedative/hypnotic genus is read to include sodium oxybate/GHB. However, absent an express GHB/oxybate species with the recited dissolution profile and IR/CR ratio, it is not a clean §102 reference; more naturally §103 (combine with a GHB teaching).

(c) US 4,227,778 — Fisons (1979/1980) — §102(b)

• Disclosure: generic prolonged‑release pharmaceutical preparations.
• Anticipates: only the general sustained‑release concept; no GHB and no claimed dissolution profile → not anticipatory of claims 1–22; §103 background at most.

(d) US 4,393,296 — Klosa (1983) — §102(b) and US 4,393,236 — GHB salts

• Disclosure: production of non‑hygroscopic GHB salts (e.g., calcium oxybate); GHB salt chemistry generally.
• Anticipates: only the salt‑identity limitations of claims 6/7 (calcium/sodium salts) in isolation; they do not disclose the controlled‑release architecture, IR portion, or dissolution limits → not anticipatory of any full claim.

(e) WO 2006/053186 — Frucht (2006‑05‑26) — §102(b)

• Disclosure: open‑label clinical use of sodium oxybate in movement disorders.
• Anticipates: nothing in the formulation claims; it is a method‑of‑use/published‑study reference.

(f) US 2010/0112056 A1 / US 8,771,735 — Rourke et al. (filed ~2008; pub. 2010‑05‑06 / granted 2014) — §102(e) candidate

• Disclosure: immediate‑release sodium oxybate dosage forms.
• Potentially anticipates: the immediate‑release‑portion limitations of claim 1(b) if the reference's IR oxybate content (and its relationship to total drug) is shown; but it does not disclose the sustained‑release functional coating over a core or the claimed >90%/8 h and 4–6 h release profile → not anticipatory of full claim 1; relevant at most to dependent IR‑portion claims.

Net §102 conclusion: Within the art I could verify, no reference discloses every limitation of granted claim 1 (or its dependents) as required for anticipation. The closest §102(b) candidates are US 2006/0210630 A1 (Liang) and WO 2007/103200 A2 (Watson); every other qualifying reference discloses only a subset (salt identity, generic SR platform, or IR forms). The granted claims appear designed around the specific dissolution profile + IR:CR drug‑loading ratios, which is what defeated Avadel's invalidity challenge at the March 2024 trial (consistent with the previously generated litigation summary: the jury found Avadel failed to prove the '488 patent invalid).

7. Caveats and items requiring direct verification

1. Incomplete citation pull. I retrieved the FPO US‑reference list only in part (truncated after ~US 8,731,963) and did not retrieve the complete foreign‑document list, the examiner's NPL "Other References," or the examiner/applicant distinction. The complete front page should be pulled directly from the USPTO PatentCenter / Google Patents "References Cited" tabs to close this gap.
2. Claim 11 text not retrieved — cannot map references to claim 11 with confidence.
3. IDS vs. relied‑upon art. Many cited references post‑date the 2010 priority (e.g., the 2016–2019 GHB/Auspex/Flamel art); these were most likely applicant IDS submissions or background citations and are not §102 prior art absent a §102(e) hook. Treating them as anticipation art would be an error.
4. Potential §102(e) family art. Several Jazz/common‑assignee patents (Allphin US 8,901,173; Rourke US 8,778,398/8,771,735) may qualify under pre‑AIA §102(e) if their applications were filed before the '488 invention date; I could not verify their exact filing dates within budget.
5. PTAB activity. I encountered USPTO PTAB petition documents (ptacts.uspto.gov petitions 1463786 and 1464494) containing oxybate controlled‑release claim language that may relate to this patent family (claim numbering 23–44 with "controlled release dosage form / immediate release formulation" language). I could not confirm which patent those petitions target, so I neither attribute them to the '488 patent nor rely on them. This should be verified against the PTAB docket.
6. Contradiction flagged (per instructions): priority date 2010‑03‑24 (Google Patents / prior section) vs. 2010‑03‑23 (Unified Patents portal); similarly grant 2020‑09‑01 vs. 2020‑08‑31. Reported literally, not reconciled.

Sources used

• US 10,758,488 full text (Google Patents): https://patents.google.com/patent/US10758488/en
• FreePatentsOnline US‑reference list: https://www.freepatentsonline.com/10758488.html
• Unified Patents patent page ("Patent Art" list): https://portal.unifiedpatents.com/patents/patent/US-10758488-B2
• Claim text and Example disclosures (US10758488B2 PDF): https://patentimages.storage.googleapis.com/75/6e/14/610288c516e485/US10758488.pdf
• Avadel investor filings (litigation/patent‑in‑suit record): https://investors.avadel.com/static-files/bd3ddb38-8b30-4fcc-b3f7-1ffde29a8f94
• USPTO PTAB petition documents (unverified target): https://ptacts.uspto.gov/ptacts/public-informations/petitions/1463786 ; .../1464494

I'll research the prior art landscape for this patent, focusing on the references cited in the patent itself and related controlled-release oxybate art.

Excellent — this surfaced extensive litigation and prosecution record. Let me pull the actual claim text of the '488 patent and its cited prior art.

Let me pin down the remaining prior-art references cited during prosecution (notably "Conte 1997") and any PTAB proceedings.

Obviousness Analysis — US 10,758,488 B2 under 35 U.S.C. § 103

0. Scope, sources, and a critical threshold issue

This analysis builds on the previously generated Patent Summary and Litigation Summary. It does not repeat them. Two threshold points first:

(a) Source note. The prompt instructs me to "use the results from the Prior Art section of this page." No discrete "Prior Art" list was supplied in the user message, and my tools returned bibliographic/prosecution data rather than a curated prior-art table. I therefore ground the analysis in (i) the references actually cited or discussed in the patent and its prosecution — Liáng 2006, Conte 1997, U.S. 4,393,236, U.S. 4,393,296, WO 2006/053186 (Frucht), and U.S. 5,594,030 — plus (ii) the "Prior art keywords" on the Google Patents face (hydroxybutyrate, gamma, controlled release, formulation, drug). All find support in the documents fetched.

(b) The effective filing date controls everything. Per the litigation record, Jazz added the two limitations that carry the claims — the "one or more methacrylic acid-methyl methacrylate co-polymers … about 20% to about 50% by weight of the functional coating" and the deionized-water USP-2/50-rpm dissolution profile — by amendment on March 6, 2020, during prosecution of the '487 application.¹ The written-description/enablement and derivation issues were vigorously contested (Avadel's D. Del. counterclaims, C.A. No. 22-cv-00487-GBW; Avadel's invalidity expert report). If those limitations are not supported by the March 24, 2011 parent disclosure, the claims are not entitled to the 2010-03-24 priority date and instead take the July 2, 2018 actual filing date of application 16/025,487. That single fact materially expands the § 103 prior-art field, because Avadel's own '284 publication (published Jan. 25, 2018) and the '062/'866 family then qualify as prior art. I flag this as an alternative (not the primary) theory, and I take the patent's asserted 2010-03-24 priority date as the baseline for the combinations below.

1. The person of ordinary skill in the art (POSA)

A POSA here would be a pharmaceutical formulation scientist (Ph.D. or M.S. in pharmaceutics/chemical engineering, or B.S. with ~3–5 years' experience) experienced in oral modified-release dosage-form development, specifically: (i) matrix and reservoir/membrane-controlled release tablets and multiparticulates; (ii) functional film coatings (ethylcellulose, methacrylate copolymers), pore-formers, plasticizers and anti-tack agents; and (iii) in-vitro dissolution testing (USP App. 2/7). The POSA would be familiar with sodium oxybate (Xyrem®), its ~45-minute plasma half-life and twice-nightly dosing, and with the once-nightly formulation problem. This skill level is well within the ordinary/advanced range and is not contested by the intrinsic record.

2. The claims at issue

Claim 1 (independent, formulation) — reconstructed verbatim from the D. Del. claim-construction opinion:²

"A formulation comprising immediate release and sustained release portions, each portion comprising at least one pharmaceutically active ingredient selected from gamma-hydroxybutyrate and pharmaceutically acceptable salts of gamma-hydroxybutyrate, wherein:
a. the sustained release portion comprises a functional coating and a core … wherein the functional coating comprises one or more methacrylic acid-methyl methacrylate co-polymers that are from about 20% to about 50% by weight of the functional coating; the sustained release portion comprises about 500 mg to 12 g of [GHB/salt]; and the sustained release portion releases greater than about 40% of its gamma-hydroxybutyrate by about 4 to about 6 hours when tested in a dissolution apparatus 2 in deionized water at 37 °C and 50 rpm;
b. the immediate release portion further comprises one or more [binders] …, and the amount of GHB … in the immediate release portion is about 10% to 50% by weight of total GHB …;
c. the formulation releases at least about 30% of its GHB … by one hour [USP-2, DI water, 37 °C, 50 rpm]; and
d. the formulation releases greater than about 90% of its GHB … by 8 hours [same conditions]."

Claim 11 (independent, method) is the companion method-of-treatment claim — a method of treating cataplexy or excessive daytime sleepiness associated with narcolepsy by delivering a formulation having IR + solid SR portions with the same MAMM/DI-water/dissolution framework. (Verbatim claim 11 text was not fully retrievable; treat as medium confidence — consistent with the prior section.)

Common to every independent claim: (1) GHB/oxybate as the drug; (2) IR + SR in one unit dosage form; (3) a functional coating containing 20–50 wt% MAMM copolymer; and (4) a pH-independent (deionized-water) dissolution profile (≥30% @1 h; >40% @4–6 h; >90% @8 h).

3. The prior-art references

The patent's own prosecution history is powerful evidence here: the Examiner rejected the original '487 claims as obvious over Liang 2006 (alone or in view of Conte).³ The applicant only escaped by (i) substituting "sustained" for "controlled," (ii) adding the MAMM 20–50% limitation, and (iii) adding the DI-water/50-rpm/50-mg-coating dissolution limitations.³ A final Certificate of Correction even had to fix claim 3's redundant "dissolution apparatus 2" language — underscoring that these dissolution limitations were late-stage additions.

4. Combination theories that render the claims obvious

Combination A (primary): Liang 2006 + U.S. 5,594,030 + the ordinary skill in film-coated reservoir systems

Disclosure mapping to claim 1:

Motivation to combine. (1) Same field, same problem, same drug: both Liang and U.S. 5,594,030 expressly address the twice-nightly GHB dosing burden; Liang states the object is a single nightly dose. (2) Known problem + known finite solutions: GHB's ~45-min half-life and high water solubility are recited in the '488 specification as the reason a CR form is needed — the same rationale the art already supplies. (3) Explicit lead from Liang: Liang itself teaches that release rate is adjusted by "altering thickness and/or composition of the coating compositions" — a direct invitation to substitute/optimize the coating polymer and its proportions. (4) Conte supplies the general matrix/layer engineering for modulating dissolution of soluble drugs, addressing the film/matrix permeability problem the '488 spec highlights.

Reasonable expectation of success. Cellulose- and methacrylate-based reservoir films with water-soluble pore-formers are among the most predictable technologies in oral CR design. Because GHB is rapidly and almost completely water-soluble, the release rate is dominated by film permeability (pore-former level) and coat weight — precisely the two variables the references say to tune. A POSA would reasonably expect to reach a ≥30% @1 h / >40% @4–6 h / >90% @8 h profile by routine optimization; U.S. 5,594,030 already achieves ~90% by 7–8 h for the same drug.

KSR rationales. The claimed subject matter is a combination of known elements (GHB + IR/SR architecture + a MAMM-containing functional coat) according to known methods, yielding no more than predictable results; the coating composition is selected from a finite set of known CR film polymers/pore-formers; and the dissolution numbers are the product of routine optimization (In re Aller). The strength of the DI-water/50-rpm limitations as a distinction is undercut by the fact that they were added by amendment and that Liang reports GHB dissolution for coatings containing MAMM copolymers.(^1)

Combination B: Liang 2006 + Avadel '284 publication (US 2018/002842-equivalent) as § 102(a)(1) art — contingent on loss of the 2010 priority date

If the MAMM-20–50% and DI-water limitations lack written-description support in the 2011 parent (Avadel's express litigation theory; the '284 publication published Jan. 25, 2018, before the July 2, 2018 filing), then Avadel's own disclosure becomes prior art. Avadel contended the '284 publication describes oxybate formulations with IR + SR portions, a functional coating containing MAMM copolymers at ~20–50 wt%, the recited USP-2/37 °C dissolution profiles, and once-nightly suitability.(^4) Under this theory, claim 1 is not merely obvious but arguably anticipated (a § 102 question), and claim 11 (method) would be obvious over the '284 publication in view of the Xyrem label. This pathway should be confirmed against the actual priority-date ruling, which is not in my retrieved materials.

Combination C (claim 11 method): any of A/B + Frucht (WO 2006/053186) / the Xyrem label

The only extra element of claim 11 is the indication — treating cataplexy or EDS in narcolepsy. That is squarely disclosed: Liang ¶1–5 and the '488 background recite GHB's use "in the treatment of narcolepsy," and Frucht confirms sodium oxybate produces dose-dependent clinical benefit and is tolerated. The motivation to administer the known CR GHB form to the known narcolepsy population is the once-nightly convenience Liang expressly seeks. Thus claim 11 adds nothing patentable to the composition claims.

Combination D: Alternative use of enteric-coating art (Liang + conventional Eudragit/pore-former teachings)

Liang's pH-dependent delayed-release approach can be modified by the general knowledge that (i) methacrylic acid-methyl methacrylate copolymers are the standard members of the enteric coating class and (ii) blending them with a water-insoluble film former/pore former produces a mixed functional coat. The '488 specification concedes these copolymers are usable "as part or all of the pore former" — i.e., the applicant itself treats MAMM-in-functional-coat as a known technique. This is a classic "obvious to try" scenario within a finite, well-enumerated set.

5. Anticipated counterarguments (and how they cut)

The patent owner's rebuttal to a Liang-based § 103 case is substantial and was actually litigated:

1. Delayed vs. sustained release. Jazz argued (and the court's construction rejected importing the limitation) that Liang is delayed-release — a bolus released within ~1 h of reaching intestinal pH — whereas the claims require gradual, extended release in DI water.² This is the strongest non-obviousness argument because Liang's own figures show a pH-triggered, near-complete release, not the flat >40% @4–6 h curve claimed.
2. The 20–50% MAMM range is not expressly disclosed. The parties agreed Liang does not expressly disclose either the 20–50% MAMM limitation or the DI-water profile (per the Jefferies trial analysis of the Joint Statement of Facts). That agreement weakens a pure § 102/anticipation theory but not obviousness, where the range would be reached by routine optimization of a disclosed component (Eudragit FS 30 D).
3. Unexpected results / secondary considerations. Jazz relied on regional-absorption and PK modeling (Allphin Declaration) showing the claimed DI-water profile targets jejunum/ileum for superior bioavailability vs. Liang's colon-targeting DR-1.³ If substantiated and not attributable to features already in the art, this is the most promising secondary-consideration argument.
4. Prosecution disclaimer. Avadel argued Jazz clearly surrendered "delayed release" scope by its "sustained release" amendment — a claim-scope issue that, if anything, narrows the claims relative to Liang.

On balance, the prima facie § 103 case is strong (the Examiner made one over Liang/Conte), and the ultimate validity depends on whether the secondary considerations and the pH-independent-profile distinction would overcome it — which the jury never had to resolve, because it found no infringement of the '488 while rejecting Avadel's invalidity proofs.(^5)

6. Bottom line

• Strongest combination: Liang 2006 (US 2006/0210630) + U.S. 5,594,030 + Conte 1997 + ordinary film-coating knowledge, with Frucht/Xyrem label supplying the treatment indication for claim 11. Together these disclose every structural element (GHB, IR+SR, functional coat with MAMM copolymer, high dose) and render the dissolution numbers the product of routine optimization, with an express motivation (once-nightly dosing) and a reasonable expectation of success (predictable pore-former/coat-weight tuning; 90% release in 7–8 h already achieved for GHB).
• Fallback/stronger if priority is lost: Avadel's '284 publication (pub. Jan. 25, 2018) becomes § 102(a)(1) art and, per Avadel, discloses the full claimed subject matter.
• Chief risk to the § 103 case: the applicant's demonstrated bioavailability advantage of the DI-water (pH-independent) profile over Liang's pH-dependent DR, if independently corroborated and not shown to inhere in the prior art.

Confidence: Claim 1 text = high (quoted from the D. Del. opinion). Claim 11 verbatim = medium. Priority-date exposure and the precise per-patent verdict = medium (would require the Delaware judgment). The overall § 103 conclusions are my analysis of the cited record, not a legal opinion.

Citations

1. Jazz v. Avadel, D. Del. C.A. No. 21-691-GBW — Joint Claim Construction Brief and exhibits (Jazz's March 6, 2020 amendment; Allphin Declaration): litigationtracker.law.georgetown.edu … /Jazz-Pharmaceuticals-Inc._2022.07.29_JOINT-CLAIM-CONSTRUCTION-BRIEF.pdf and …_JOINT-CLAIM-CONSTRUCTION-APPENDIX.pdf.
2. Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, claim construction opinion (D. Del.), https://www.ded.uscourts.gov/sites/ded/files/opinions/21-691_0.pdf.
3. Jazz's Motion for Partial Summary Judgment of Nonobviousness (D. Del., Nov. 30, 2023), litigationtracker.law.georgetown.edu … /Jazz-Pharmaceuticals-Inc._2023.11.30_PLAINTIFFS-MOTION-FOR-PARTIAL-SUMMARY-JUDGMENT…pdf; Avadel invalidity expert report, https://storage.courtlistener.com/recap/gov.uscourts.ded.75471/gov.uscourts.ded.75471.357.0.pdf.
4. Avadel '284 publication content as described in Avadel's expert report, supra n.3, ¶¶ 425–427.
5. Avadel SEC disclosure ("On March 4, 2024, the jury returned a verdict of no infringement for U.S. Patent No. 10758488…"), https://investors.avadel.com/static-files/a58979ca-12ee-48f2-8418-be669c305caf.
6. Liang 2006, US 2006/0210630 A1, https://patentimages.storage.googleapis.com/49/fb/f1/cdc02554704913/US20060210630A1.pdf and https://www.freepatentsonline.com/y2006/0210630.html.
7. Full patent text, https://patents.google.com/patent/US10758488/en.